InspireMD Inc. (NSPR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.45 (-0.31% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.2 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While NSPR currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.47) forces dealer call-delta covering toward $2.52.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
InspireMD Inc. (NSPR) slipped -0.31% to $0.45, trading at 2% of its 52-week range ($0.43 – $2.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Benzinga report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +28.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NSPR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NSPR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, InspireMD Inc. (NSPR) ranks #735 by composite RQD confidence (32/100, grade E) and #827 by equity capitalization ($20.9M). Within this direct 5-issuer industry benchmark cohort, NSPR leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NSPR at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NSPR
ACTIVE
InspireMD Inc. | E | 32/100 | — | 29.5% | -35.0% | -0.31% | $20.9M | Benchmark Subject |
| PMI Picard Medical Inc. | D | 48/100 | — | — | — | +2.96% | $20.5M | /pmi-vs-nspr → |
| RVP Retractable Technologies Inc. | E | 31/100 | — | 0.1% | -23.3% | -1.96% | $16.9M | /rvp-vs-nspr → |
| PLRZ Polyrizon Ltd. | E | 34/100 | — | — | -25.1% | +19.40% | $26.1M | /plrz-vs-nspr → |
| MODD Modular Medical Inc. | E | 33/100 | — | — | -35.0% | 0.00% | $16.3M | /modd-vs-nspr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), InspireMD Inc. (NSPR) reported GAAP revenue of $9.0M (+28.1% vs. FY2024 revenue of $7.0M , and +44.7% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$35.1M, and free cash flow of -$36.8M (-58.0% YoY). On the balance sheet, NSPR closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.0M | -$48.8M | -$35.1M | -$36.8M | $69.4M | — |
| FY2024 (FY) | 2024-12-31 | $7.0M | -$32.0M | -$21.9M | -$23.3M | $46.8M | — |
| FY2023 (FY) | 2023-12-31 | $6.2M | -$19.9M | -$16.4M | -$16.4M | — | — |
As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.45 (-0.31% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NSPR last traded at $0.45 (-0.31% on volume of 478,664 shares), positioning the stock -30.77% below its 50-day simple moving average ($0.65) and -57.55% below its 200-day simple moving average ($1.06). Across its 52-week range of $0.43 to $2.40, NSPR sits at the 1.0% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.51).
Why NSPR Stock slipped -0.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, NSPR scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Implications for a prospective investor evaluating the stock today: the rating points to weak cash generation, low institutional and insider conviction, and forensic caution. Any upside case would need to rest on a turnaround in operating economics, which the source data does not show. The valuation context is a $0.45 share price against a $21.0M market cap, with the stock trading in a $0.43 – $2.4 range over 52 weeks. The price sits near the bottom of that range, which reflects the deterioration captured by the RQD pillars rather than a signal of undervaluation on its own.
InspireMD Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, it is a Health Care issuer operating in Medical/Dental Instruments. The source data does not describe its specific products, customers, or detailed revenue model. Revenue is reported in the financials at $9.0M for FY 2025.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $9.0M | $-49.6M | $-48.8M | N/A | $-36.8M | $8.9M | N/A |
| FY 2024 | $7.0M | $-33.5M | $-32.0M | N/A | $-23.3M | $18.9M | N/A |
| FY 2023 | $6.2M | $-21.1M | $-19.9M | N/A | $-16.4M | N/A | N/A |
Per the SEC financials, revenue rose from $6.2M in FY 2023 to $9.0M in FY 2025, while operating losses widened from $-21.1M to $-49.6M over the same span. Per the market data, gross margin is 29.5%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9. Per the SEC financials, cash declined from $18.9M in FY 2024 to $8.9M in FY 2025, and debt is not available in source data.
Per the recent news and catalysts section, the most recent items are market-wire coverage. Headlines include a Benzinga pre-market report that mentions NSPR among health care movers, an announcement that InspireMD will report third quarter 2026 financial results, a technical-level report noting the stock climbing 8.5% to $0.52 and reclaiming the $0.50 level, and two Traders Union stock and technical analysis pages. Each item is marked YELLOW in the source and categorized as MARKET WIRE. The source does not provide substantive detail on the content of the third quarter 2026 results announcement. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care / Medical/Dental Instruments classification and the Roarable RQD beta reading of 1.0.
Per the analyst data section: NONE. Consensus rating and price targets are not available in source data.
Per the holders section: NONE. Insider Form 4, 13F whale, and Congressional trade details are not available in source data.
Real-time company headlines, analyst actions, and sector developments for InspireMD Inc. (NSPR) • Click "Debate This Headline" to argue it in the Roar Pit below
Benzinga report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering InspireMD Inc. (NSPR) market action, institutional positioning, and fundamental catalysts.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards
Welcome to the NSPR (InspireMD Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on NSPR, but look at what you are paying: current EV/EBITDA multiples with 29.5% gross margins. Unless InspireMD Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on NSPR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.45 (52-wk range $0.43 - $2.40), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).